
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division
Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sa…
Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sa…
Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company’s acceleration be…
2D-BioPAD and MUNASET hosted a joint workshop on the 17th of October 2024, during the Graphene Week 2024, aimed at foste…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard), ein onkologisches Plattformunternehmen, d…
Financial Highlights Direct MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, fro…
Bayer und Asklepios BioPharmaceutical, Inc. (AskBio), ein Gentherapie- Unternehmen und hundertprozentige, unabhängig bet…
Financial Highlights Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; th…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…